Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Stock data | 2024 | Change |
---|---|---|
Price | $3.65 | N/A |
Market Cap | $155.07M | N/A |
Shares Outstanding | 42.49M | N/A |
Employees | 105.00 | N/A |